Obesity最新文献

{"title":"Adipose Tissue-Derived Small Extracellular Vesicles in Plasma Reveal Molecular Circuitries Underlying Glucose Intolerance","authors":"Shalini Mishra,&nbsp;Yixin Su,&nbsp;Ashish Kumar,&nbsp;Sangeeta Singh,&nbsp;Brian S. Finlin,&nbsp;Fang-Chi Hsu,&nbsp;Jingyun Lee,&nbsp;Cristina M. Furdui,&nbsp;Philip A. Kern,&nbsp;Swapan K. Das,&nbsp;Gagan Deep","doi":"10.1002/oby.70157","DOIUrl":"10.1002/oby.70157","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Glucose tolerance (GT) is a major effector for adipose tissue (AT) remodeling in obesity, yet its molecular mechanisms remain incompletely defined. We hypothesized that the biophysical and molecular profiles of AT-derived small extracellular vesicles (sEV^AT) change in response to glucose availability and differ by GT status.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>sEV^AT were isolated from plasma of individuals with normal GT (NGT) and impaired GT (IGT) (<i>n</i> = 5/group) at fasting (0 h) and 1 h post glucose challenge during oral glucose tolerance test (OGTT). sEV^AT were characterized for size, concentration, surface expression of insulin receptor-α (INSRα), proteome, and insulin signaling-related miRNAs. C2C12 myotubes were treated with sEV^AT for 48 h, followed by quantification of 84 insulin signaling-related genes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Result</h3>\u0000 \u0000 <p>The size and concentration of sEV^AT did not differ between groups. At fasting, INSRα expression on sEV^AT was comparable; however, groups exhibited opposite directional changes at 1-h OGTT. LC–MS/MS identified significant proteomic differences between NGT and IGT sEV^AT. miR-27a-5p and miR-145a-5p levels in sEV^AT also differed significantly by GT status. Notably, treatment with sEV^AT (IGT-0 h) significantly downregulated insulin signaling-related genes in myotubes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Distinct molecular signatures in sEV^AT offer a unique insight into AT dysfunction during IGT and offer novel diagnostic and therapeutic targets.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 4","pages":"896-907"},"PeriodicalIF":4.7,"publicationDate":"2026-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13032056/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147273622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cholecystectomy Is Linked With Lower Respiratory Exchange Ratio and Higher Lipid Oxidation and Sleep Energy Expenditure","authors":"Beyza N. Aydin,&nbsp;Emma J. Stinson,&nbsp;Helen C. Looker,&nbsp;Peter Walter,&nbsp;Tomás Cabeza de Baca,&nbsp;Jonathan Krakoff,&nbsp;Douglas C. Chang","doi":"10.1002/oby.70145","DOIUrl":"10.1002/oby.70145","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Cholecystectomy (GBX) may alter energy metabolism, but human evidence is limited. We examined whether GBX alters energy expenditure (EE), respiratory exchange ratio (RER), and substrate oxidation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A total of 384 healthy Southwestern Indigenous American adults (222 males, age 28 ± 6 years) were studied, including individuals with a history of gallbladder surgery [GBX(+), <i>n</i> = 39] and without surgery [GBX(−), <i>n</i> = 345]. In addition, 24-h energy metabolism was measured in a respiratory chamber. General linear models were adjusted for age, sex, body composition, and glucose regulation. RER and macronutrient oxidation rates were further adjusted for energy balance.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>GBX(+) participants were older (31 ± 7 vs. 27 ± 6 years, <i>p</i> = 0.0002) and mostly female (95% vs. 36%, <i>p</i> &lt; 0.0001), and they had higher body fat (40% ± 5% vs. 32% ± 8%, <i>p</i> &lt; 0.0001), although body composition differences were sex related. Adjusted models showed lower RER (<i>β</i> = −0.01, <i>p</i> = 0.01), higher lipid oxidation (<i>β</i> = 79 kcal/day, <i>p</i> = 0.03), and higher sleep EE (<i>β</i> = 78 kcal/day, <i>p</i> = 0.006) in the GBX(+) group. Other EE variables and macronutrient oxidation rates were not significantly associated with GBX history (all <i>p</i>'s &gt; 0.1).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Independent of obesity, an absent gallbladder is associated with decreased RER and increased lipid oxidation and sleep EE rates, indicating that the gallbladder may have a role in metabolic fuel selection that has implications for metabolic health.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>\u0000 ClinicalTrials.gov identifiers: NCT00339482, NCT00340132</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 4","pages":"793-800"},"PeriodicalIF":4.7,"publicationDate":"2026-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13032049/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146168649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Calorie Restricted Diet Versus Liraglutide on Intrapancreatic Fat Deposition in People With Obesity: A Pilot Study","authors":"Haiyan Cheng,&nbsp;Xiao Jiang,&nbsp;Xiaowei Zhu,&nbsp;Xiaowen Zhu,&nbsp;Chenxi Li,&nbsp;Mengjiao Cao,&nbsp;Qunyan Zhou,&nbsp;Shukun Deng,&nbsp;Wenjun Wu","doi":"10.1002/oby.70153","DOIUrl":"10.1002/oby.70153","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This pilot study compared the effects of a calorie restricted diet (CRD) versus liraglutide on intrapancreatic fat deposition (IPFD) in people with obesity and explored associations between changes in adiposity-related metrics and glycemic-related parameters.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this 24-week prospective nonrandomized study, participants with obesity received CRD or liraglutide. Primary endpoint was the change in pancreatic fat fraction (PFF). Secondary endpoints included changes in body weight, liver fat fraction (LFF), visceral fat area (VFA), and glycemic-related parameters.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Both CRD (<i>n</i> = 23) and liraglutide (<i>n</i> = 23) demonstrated significant and comparable reductions in PFF (time effect: <i>p</i> &lt; 0.001; interaction effect: <i>p</i> = 0.560). Significant and similar improvements were also observed in body weight, LFF, VFA, HbA1c, HOMA2-IR, and ISIM (all time effects: <i>p</i> &lt; 0.001; all interaction effects: <i>p</i> &gt; 0.05). Regression analysis indicated that ΔHOMA2-IR was positively associated with Δweight and ΔLFF but negatively with ΔPFF, while ΔISIM was negatively associated with ΔVFA and positively with ΔPFF.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Both CRD and liraglutide significantly and similarly reduce pancreatic, liver, and visceral fat, while improving glycemic-related parameters in people with obesity. Preliminary findings suggest liver and visceral fat loss primarily drive improved insulin resistance, whereas pancreatic fat reduction may relate to subtler insulin dynamics changes, warranting further investigation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>This study is a sub-study of the registered trial ChiCTR1900022948</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 4","pages":"829-838"},"PeriodicalIF":4.7,"publicationDate":"2026-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147286796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Genetic Predisposition to Obesity on Long-Term Maintenance of Modest Weight Loss in Postmenopausal Women","authors":"Harold H. Lee,&nbsp;Christy L. Avery,&nbsp;Misa Graff,&nbsp;Daeeun Kim,&nbsp;Josh Arias,&nbsp;Linda Van Horn,&nbsp;Charles Kooperberg,&nbsp;Kari E. North","doi":"10.1002/oby.70175","DOIUrl":"10.1002/oby.70175","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Long-term weight regain limits the population-level benefits of obesity interventions. We tested whether the polygenic risk score of BMI (PRS_BMI) modifies weight trajectories following modest weight loss.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The analytic sample included 9897 postmenopausal women from the Women's Health Initiative Dietary Modification Trial (6132 European American; 3749 African American). PRS_BMI was derived from a trans-ancestry GWAS of ~2 million participants. Longitudinal weight change (7 years) was modeled using weighted GEE.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In European Americans, the PRS_BMI × randomization × time interactions approached significance at the 95th percentile (<i>p</i> = 0.052) and 85th percentile (<i>p</i> = 0.07). No interaction was observed in African Americans. In analyses restricted to European Americans who lost ≥ 5% of initial weight by year 1 (20%; <i>n</i> = 1273), women in the ≥ 95th percentile of PRS_BMI regained nearly twice as much per year as those with average risk (0.94 vs. 0.48 kg/year, <i>p</i> = 0.0016).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>A high PRS_BMI was associated with faster weight regain following modest weight loss in European American women. While further validation is required in a diverse population, these results suggest the potential for genetics to inform targeted strategies for sustaining long-term weight management.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>\u0000 ClinicalTrials.gov identifier: 75N92021D00001, 75N92021D00002, 75N92021D00003, 75N92021D00004, and 75N92021D00005</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 4","pages":"782-786"},"PeriodicalIF":4.7,"publicationDate":"2026-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13032054/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147370952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TOS/OMA/OAC Expert Guidance Statement on Obesity Pharmacotherapy: A Humbling Call to Action","authors":"Beverly G. Tchang,&nbsp;Donna H. Ryan","doi":"10.1002/oby.70170","DOIUrl":"10.1002/oby.70170","url":null,"abstract":"&lt;p&gt;In 2013, obesity stepped into a momentous spotlight: the American Medical Association declared obesity a disease, and in the same year, after sponsorship by the National Institutes of Health, multiple professional societies published guidelines on obesity care, a 5-year effort that included recommendations on dietary intervention, lifestyle intervention, and bariatric surgery but was silent on obesity medications due to lack of evidence [&lt;span&gt;1&lt;/span&gt;]. Over the subsequent decades, several advancements in the treatment of obesity have shifted public understanding, expectations, and goals. Today, the leading scientific professional organization. The Obesity Society (TOS) and its clinical and patient advocacy partners Obesity Medicine Association (OMA) and Obesity Action Coalition (OAC) share with us an evidence-based overview of obesity pharmacotherapy—its strengths and weaknesses, highlights and blind spots, and current achievements and future potentials [&lt;span&gt;2&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;The TOS/OMA/OAC Expert Guidance Statement is distinct in its purpose, with a clear goal of avoiding redundancy with other guidelines and consensus statements [&lt;span&gt;3-6&lt;/span&gt;]. The general prescriber will &lt;i&gt;not&lt;/i&gt; find user-friendly algorithms in this document as such resources have already been expertly developed elsewhere. Instead, this statement approaches the evidence base for obesity pharmacotherapy from a radically different perspective, with the pioneering inclusion of a patient advocacy group, to ask if and how current literature is supporting patients' goals rather than synthesize the literature to reiterate values held by the traditional medical system. This was achieved by partnership with Replica Communications, a strategic research and knowledge mobilization firm. The guidance is also a remarkable achievement in efficiency—it was accomplished in less than a year, thanks to support by Epistemonikos Foundation, a health research methodology nonprofit based in Chile, which used artificial intelligence (AI) to generate the evidence tables that were then reviewed by expert panelists to draft and finalize the recommendations.&lt;/p&gt;&lt;p&gt;With patient-centered outcomes in mind, the committee delineated the priority of outcomes based on patients' inputs and their relative importance (Expert Guidance Statement Table 3). While some outcomes were expectedly highly prioritized (e.g., mortality), others represent a growing understanding of how patient-centered outcomes encompass more than obesity-related complications or diseases (ORCDs): uniquely, quality of life was deemed to be equally important as morbidity and mortality. In contrast to prior guidelines with similar methodology [&lt;span&gt;4&lt;/span&gt;], weight loss was not identified as a “critical” outcome, reflecting the evolution of patients' goals to access benefits of obesity treatment beyond weight loss.&lt;/p&gt;&lt;p&gt;Fifteen questions around these outcomes of interest were developed by the panel representing scientists and cli","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 4","pages":"765-769"},"PeriodicalIF":4.7,"publicationDate":"2026-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.70170","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147358254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obstructive Sleep Apnea Following Bariatric Surgery: 20 Year Outcomes From the Swedish Obese Subjects Study","authors":"Ida Arnetorp,&nbsp;Markku Peltonen,&nbsp;Kajsa Sjöholm,&nbsp;Per-Arne Svensson,&nbsp;Peter Jacobson,&nbsp;Magdalena Taube,&nbsp;Lena M. S. Carlsson,&nbsp;Johanna C. Andersson-Assarsson,&nbsp;Sofie Ahlin","doi":"10.1002/oby.70154","DOIUrl":"10.1002/oby.70154","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Bariatric surgery has been suggested to improve obstructive sleep apnea (OSA) in short-term studies, but long-term evidence is limited. We evaluated remission and new onset of OSA over 20 years in participants from the Swedish Obese Subjects (SOS) study, comparing bariatric surgery with usual obesity care.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The SOS study is a nonrandomized, controlled intervention study including 4047 individuals who received bariatric surgery (<i>n</i> = 2010) or usual obesity care (<i>n</i> = 2037). OSA status was assessed via questionnaires at baseline and at 1, 2, 3, 4, 6, 8, 10, 15, and 20 years. We examined remission and new onset of OSA among participants with or without the condition at baseline, comparing surgery to usual care.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>On average over 20 years, bariatric surgery was associated with a 32.1 percentage points lower prevalence of OSA in participants with baseline OSA (95% CI: −36.9 to −27.2; <i>p</i> &lt; 0.001) compared to usual care. Among those without baseline OSA, surgery patients had a 5.8 percentage points lower prevalence of new-onset OSA (95% CI: −7.1 to −4.6; <i>p</i> &lt; 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Bariatric surgery was associated with durable OSA benefits, including higher remission and lower long-term new onset of OSA compared to usual obesity care.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>\u0000 ClinicalTrials.gov identifier: NCT01479452</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 4","pages":"819-828"},"PeriodicalIF":4.7,"publicationDate":"2026-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13032045/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147286883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Voice of a Disease: Why Food Noise Can No Longer Be Ignored!","authors":"Abdulhameed Alhazmi,&nbsp;Carel W. le Roux","doi":"10.1002/oby.70161","DOIUrl":"10.1002/oby.70161","url":null,"abstract":"&lt;p&gt;Diktas et al. [&lt;span&gt;1&lt;/span&gt;] present a rigorous study establishing the Food Noise Questionnaire (FNQ) as the first validated tool to quantify intrusive food-related thoughts in individuals with overweight and obesity. The authors demonstrate psychometric reliability and validity, providing a practical measure to the neurobehavioral construct. Their findings represent a step toward operationalizing food noise (FN) as a measurable phenomenon rather than a subjective experience. However, while the FNQ's validation is a major advance, the clinical interpretation of FN and its potential role as a disease activity marker remain to be explored.&lt;/p&gt;&lt;p&gt;The struggle with obesity is not simple as a battle of willpower. The disease of obesity is complex and has a much deeper brain-gut relation than thought [&lt;span&gt;2&lt;/span&gt;]. The hypothalamus regulates adipocyte mass by integrating hormonal and neural signals from the gut and adipose tissue to maintain energy homeostasis [&lt;span&gt;2&lt;/span&gt;]. In obesity, this homeostasis becomes dysregulated, leading to persistent hunger and intrusive thoughts about eating that reflect the brain's defended higher adipocyte mass [&lt;span&gt;2&lt;/span&gt;]. These thoughts tend to be persistent, undesirable, or distressing in a noisy pattern patients call “food noise” [&lt;span&gt;1&lt;/span&gt;]. Rather than dismissing this phenomenon as a psychological lack of discipline, we must ask: could FN be a symptom, a clinical signifier of aberrant neuroendocrine signaling?&lt;/p&gt;&lt;p&gt;This concept of relying on “symptomatic urges” is no stranger to the field of endocrinology. A patient with primary adrenal insufficiency has overwhelming salt craving, which represents a behavioral adaptation to the critical, homeostatic drive stemming from aldosterone deficiency and sodium wasting [&lt;span&gt;3&lt;/span&gt;]. Thus, the symptom is so characteristic that its emergence in a patient treated with mineralocorticoid replacement signals that the treatment is insufficient.&lt;/p&gt;&lt;p&gt;Similarly, the unquenchable thirst with compulsive water drinking is a pathognomonic feature of central diabetes insipidus (CDI) and indicated vasopressin deficiency [&lt;span&gt;4&lt;/span&gt;]. While the presence of thirst is an important symptom during the management of patients with CDI, the absence of the symptom can lead to “adipsic diabetes insipidus” resulting in unrecognized hypernatremia [&lt;span&gt;4&lt;/span&gt;]. The urge to drink water is a logical, physiological response to the failure of the posterior pituitary and the resulting unregulated diuresis [&lt;span&gt;4&lt;/span&gt;]. When clinicians treat the underlying deficiency of vasopressin, the pathological thirst resolves [&lt;span&gt;4&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;What is the pathophysiological basis for FN in obesity? The current hypothesis is that FN is a symptom indicating a dysregulation of adipocyte mass. In many forms of obesity, adipocyte mass is regulated at an elevated mass resulting in the complications of obesity, a state of abnormal or excess adiposity [&lt;span&gt;2&lt;/span&gt;]. FN may repr","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 4","pages":"759-761"},"PeriodicalIF":4.7,"publicationDate":"2026-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13032050/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146168565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"C/EBPα is Essential for Gonadal but Not Inguinal White Adipose Tissue Formation in Mice","authors":"Krista Y. Hu,&nbsp;Yu-Lin Ma,&nbsp;Esme A. Dodge,&nbsp;Olivia A. B. Maguire,&nbsp;Caio V. Matias,&nbsp;Ryan P. Barney,&nbsp;Hector S. Himede,&nbsp;Juliana Gomez Pardo,&nbsp;Miriam Cepeda,&nbsp;Scott M. Gordon,&nbsp;Robert C. Bauer","doi":"10.1002/oby.70142","DOIUrl":"10.1002/oby.70142","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The distribution of excess white adipose tissue (WAT) in obesity correlates with risk for comorbidities. Thus, understanding depot-specific WAT developmental mechanisms is translationally relevant. SNPs near the gene <i>CEBPA</i> associate with waist to hip ratio, and while C/EBP<i>α</i> is a recognized regulator of adipogenesis, there is no previously known role for C/EBP<i>α</i> in regulating adipose distribution.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We crossed <i>Cebpa</i> floxed mice to the AdipoQ-Cre transgenic mouse strain, generating mice with adipocyte-specific knockout of <i>Cebpa</i> (Cebpa_ASKO). Mice were phenotyped on a chow diet and after prolonged high-fat diet (HFD) feeding.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Cebpa_ASKO mice almost entirely lack gonadal WAT (gWAT), while inguinal WAT (iWAT) is present in near normal amounts. Despite developing, Cebpa_ASKO iWAT contains fewer and larger adipocytes, fails to expand under HFD challenge, and is dysfunctional as evidenced by transcriptomics and functional studies. Finally, Cebpa_ASKO mice have lipid-laden brown adipose tissue (BAT), increased hepatic triglycerides, and increased plasma cholesterol, all of which worsen with prolonged HFD feeding.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>These results highlight a previously unrecognized difference in the essentiality of C/EBP<i>α</i> for gWAT and iWAT development and highlight novel interorgan relationships between WAT and other metabolic tissues. Further studies of these specific mechanisms could have clinical relevance for targeting visceral adiposity in humans.</p>\u0000 \u0000 <div>\u0000 \u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure>\u0000 </div>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 4","pages":"882-895"},"PeriodicalIF":4.7,"publicationDate":"2026-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13032053/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146159564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Food Noise: Current Knowledge and Future Research Directions","authors":"Devika Umashanker,&nbsp;James E. Mitchell","doi":"10.1002/oby.70149","DOIUrl":"10.1002/oby.70149","url":null,"abstract":"","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 4","pages":"762-764"},"PeriodicalIF":4.7,"publicationDate":"2026-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146159602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HDM1002 in Chinese Adults With Overweight/Obesity: A Randomized, Placebo-Controlled, Ascending-Dose Phase 1b Study","authors":"Hongrong Xu,&nbsp;Wei Hu,&nbsp;Lin Zhao,&nbsp;Wenwen Tu,&nbsp;Lijun Shen,&nbsp;Guangyang Zhang,&nbsp;Liping Zhong,&nbsp;Jing Liu,&nbsp;Junfang Xu,&nbsp;Xiaoying Li","doi":"10.1002/oby.70160","DOIUrl":"10.1002/oby.70160","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>HDM1002, a small-molecule agonist of glucagon-like peptide-1 receptors, was evaluated for safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Chinese participants (18–60 years) with BMI ≥ 24.0 kg/m² to ≤ 36.0 kg/m² without diabetes were enrolled and randomized 5:1 (12 per cohort) to receive HDM1002 or placebo orally for 28 days. Dose cohorts included 50 mg once daily (QD); 100 mg QD; 200 mg QD; 100 mg twice daily (BID); and 400 mg QD. Primary endpoint was safety, assessed by treatment-emergent adverse events (TEAEs), vital signs, physical examination, electrocardiogram, and laboratory parameters. Secondary endpoints were PK/PD analyses.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>TEAEs in 50/100/200 mg QD, 100 mg BID, and 400 mg QD HDM1002 groups were 80%, 70%, 100%, 90%, and 100%, respectively, and 60% in the placebo group, all mild/moderate. Two participants discontinued HDM1002 due to TEAEs versus none in the placebo group. Greater least squares mean reductions from baseline in body weight were among HDM1002 200 mg QD (−6.1 kg), 100 mg BID (−4.4 kg), and 400 mg QD (−4.3 kg) groups, compared with placebo (−1.6 kg). There was no significant effect on glycemia observed with HDM1002 compared to placebo. PK were generally doseproportional.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>HDM1002 demonstrated a manageable safety/tolerability profile.</p>\u0000 \u0000 <p>\u0000 <b>Trial Registration:</b> CTR20233390</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 4","pages":"839-850"},"PeriodicalIF":4.7,"publicationDate":"2026-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147391843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}